Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05411523 · ClinicalTrials.gov registry record

Assessing Effect of Spinal Cord Stimulation on Pain and Quality of Life With Chemotherapy-Induced Peripheral Neuropathy

A clinical trial of Malignant Solid Neoplasm and Hematopoietic and Lymphoid System Neoplasm, sponsored by Mayo Clinic.

Recruiting
Registry status
20
Enrollment target
1
Study location

NCT05411523 is a study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid System Neoplasm that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05411523, a study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid System Neoplasm, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
20 participants
Enrollment target
1
Study location

Study Summary

This study examines how spinal cord stimulation (SCS) affects pain level and quality of life in patients experiencing chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a nerve problem and one of the potential side effects of chemotherapy that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. CIPN usually begins in the hands or feet and gets worse over time. SCS is a type of therapy that has proven to be effective in treating numerous non-malignant pain disorders including failed back surgery syndrome, refractory angina, limb ischemia, complex regional pain syndrome, and diabetic peripheral neuropathy. SCS may also be useful in patients with CIPN. This study evaluates how SCS affects pain and quality of life in patients undergoing spinal cord stimulation for CIPN.

Conditions Studied

Malignant Solid Neoplasm Hematopoietic and Lymphoid System Neoplasm Chemotherapy-induced Peripheral Neuropathy

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Questionnaire Administration
  • PROCEDURE Spinal Cord Stimulation

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2022-04-14
Est. Completion 2027-04-15

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05411523

The ClinicalTrials.gov registry entry for NCT05411523 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (98% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.

NCT05411523 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT05411523 about?

NCT05411523 is a clinical study titled "Assessing Effect of Spinal Cord Stimulation on Pain and Quality of Life With Chemotherapy-Induced Peripheral Neuropathy". This study examines how spinal cord stimulation (SCS) affects pain level and quality of life in patients experiencing chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a nerve problem and one of the potential side effects of chemotherapy that causes pain, numbness, tingling, swelling, or mu...

What is the current status of trial NCT05411523?

This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2022-04-14. Estimated completion is 2027-04-15.

What conditions does trial NCT05411523 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm, Chemotherapy-induced Peripheral Neuropathy.

What interventions are being tested in trial NCT05411523?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Spinal Cord Stimulation (PROCEDURE).

Who is sponsoring clinical trial NCT05411523?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05411523 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Malignant Solid Neoplasm

All registered trials for this condition

Hematopoietic and Lymphoid System Neoplasm

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.